Title: Guillermo E. Umpierrez, M.D., Roma Gianchandani, M.D., Dawn Smiley, M.D., Sol Jacobs, M.D., David H. Wesorick, M.D., Christopher Newton, M.D., Farnoosh Farrokhi, M.D., Limin Peng, P.H.D. David Reyes, M.D., Sangeeta Lathkar-Pradhan, M.B.B.S., Francisco
1Guillermo E. Umpierrez, M.D., Roma Gianchandani,
M.D., Dawn Smiley, M.D., Sol Jacobs, M.D., David
H. Wesorick, M.D., Christopher Newton, M.D.,
Farnoosh Farrokhi, M.D., Limin Peng, P.H.D. David
Reyes, M.D., Sangeeta Lathkar-Pradhan, M.B.B.S.,
Francisco Pasquel, M.D.
Diabetes Care Volume 36 3430-3435 November, 2013
2STUDY OBJECTIVE
- To investigate the safety and efficacy of
sitagliptin (Januvia) for inpatient management of
type 2 diabetes (T2D) in general medicine and
surgery patients
Umpierrez G. E. et al. Diabetes Care
2013363430-3435
3STUDY DESIGN AND METHODS
- T2D patients were randomized to receive
sitagliptin alone or in combination with glargine
insulin (glargine) or to a basal bolus insulin
regimen (glargine and lispro) plus supplemental
(correction) doses of lispro - Major study outcomes
- Differences in daily blood glucose (BG)
- Frequency of treatment failures (defined as
three or more consecutive BG gt240 mg/dL or a mean
daily BG gt240 mg/dL) - Hypoglycemia between groups
Umpierrez G. E. et al. Diabetes Care
2013363430-3435
4RESULTS
- Glycemic control improved similarly in all
treatment groups - There were no differences in
- Mean daily BG after the first day of treatment
- Number of readings within a BG target of 70 and
140 mg/dL - Number of BG readings gt200 mg/dL
- Number of treatment failures
- Total daily insulin dose and number of insulin
injections were significantly less in the
sitagliptin groups compared with the basal bolus
group - There were no differences in length of hospital
stay or in the number of hypoglycemic events
between groups
Umpierrez G. E. et al. Diabetes Care
2013363430-3435
5Umpierrez G. E. et al. Diabetes Care
2013363430-3435
6Umpierrez G. E. et al. Diabetes Care
2013363430-3435
7Umpierrez G. E. et al. Diabetes Care
2013363430-3435
8CONCLUSIONS
- Treatment with sitagliptin alone or in
combination with basal insulin is safe and
effective for the management of hyperglycemia in
general medicine and surgery patients with T2D
Umpierrez G. E. et al. Diabetes Care
2013363430-3435
9Umpierrez G. E. et al. Diabetes Care
2013363430-3435